|
|
Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
|
| |
| {{CMG}} | | {{CMG}} |
|
| |
|
| |
| {{Meningitis}} | | {{Meningitis}} |
|
| |
|
| |
|
| |
|
| |
|
| <div class="mw-collapsible mw-collapsed"> | | <div class="mw-collapsible mw-collapsed"> |
Line 273: |
Line 267: |
|
| |
|
| <div class="mw-collapsible mw-collapsed"> | | <div class="mw-collapsible mw-collapsed"> |
|
| |
| ====Enterobacteriaceae and Pseudomonas aeruginosa====
| |
|
| |
| <div class="mw-collapsible-content">
| |
|
| |
| {|
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterobacteriaceae}}<sup>Ω</sup>
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 g q8–12h to 2 g IV q4h'''''<BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 1 g IV qd (2 g IV q12h for Purulent meningitis also IM in 1% lidocaine)'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h''''' <BR> ''OR'' <BR> ▸ '''''[[Fluoroquinolone]]'''''<sup>Δ</sup><BR> ''OR'' <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5–20 mg/kg/day q6-12h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> ''OR'' <BR>▸ '''''[[Ampicillin]] 150–200 mg/kg/day IV'''''
| |
| |-
| |
| |}
| |
| {|
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0";
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pseudomonas aeruginosa}}
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime ]] 1–2 g IV/IM q8–12h'''''<BR>''OR''<BR>▸ '''''[[Cefepime]] 1–2 g IV q12h'''''<sup>£</sup>
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 g q8h–2 g IV q6h'''''<BR>''OR''<BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR>''OR''<BR> ▸ '''''[[Ciprofloxacin]] 500-750 mg po bid'''''<sup>£</sup><BR><BR><BR>
| |
| |-
| |
| |}
| |
| |}
| |
|
| |
| </div></div>
| |
|
| |
|
| |
| <BR>
| |
|
| |
| †MIC=minimum inhibitory concentration.‡Addition of rifampicin can be considered if the organism is susceptible, the expected clinical or bacteriological response is delayed, or the cefotaxime/ceftriaxone MIC of the pneumococcal isolate is >4·0 μg/mLorganism is susceptible, the expected clinical or bacteriological response is delayed, or the cefotaxime/ceftriaxone MIC.ΦNo clinical data exist for use of this agent in patients with pneumococcal meningitis; recommendation is based on cerebrospinal fluid penetration and in-vitro activity against S pneumoniae.£Addition of an aminoglycoside should be considered; might need intraventricular or intrathecal administration in Gram-negative meningitis. ||Addition of rifampicin should be considered.Ω Choice of a specifi c agent should be based on in-vitro susceptibility testing. ††Might also need to be administered by the intraventricular or intrathecal routes. ǂ Might also need to be administered by the intraventricular or intrathecal routes. ₦ Addition of rifampicin should be considered.Δ The fluoroquinolones gatifl oxacin and moxifl oxacin pene trate the CSF eff ectively and have greater in-vitro activity against Gram-positive bacteria than do their earlier counterparts (eg, ciprofl oxacin). Findings from experi mental meningitis models suggested their effi cacy in S pneumoniae meningitis, including that caused by penicillin-resistant and cephalosporin-resistant strains. Although one controlled trial suggested the fluoroquinolone trovafl -oxacin mesilate to be as eff ective as ceftriaxone, with or without the addition of vancomycin, for paediatric bacterial meningitis, no clinical trials describe the use of gatifl oxacin or moxifl oxacin to treat bacterial meningitis in human beings. Trovafl oxacin and gatifl oxacin have been asso ciated with serious hepatic toxicity and dysglycaemia, respectively, and were with drawn from many markets.51 The IDSA guidelines recom mend moxifl oxacin as an alternative to third-generation cephalosporins plus vancomycin for menin-gitis caused by S pneumoniae strains resistant to penicillin and third-generation cephalosporins, although some experts recom mend that this agent should not be used alone but rather should be combined with another drug (either vancomycin or a third-generation cephalo sporin), because of the absence of clinical data supporting its use.
| |